Alpha-synuclein and its role in metal binding: Relevance to Parkinson's disease

Journal of Neuroscience Research

Volumn 86, Issue 3, 2008, Pages 496-503

  Wright, Josephine A ^a   Brown, David R ^a  

^a University of Bath   (United Kingdom)

Author keywords

Metal; Neurodegeneration; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; COPPER;

HUMAN; METAL BINDING; NONHUMAN; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; SHORT SURVEY;

ALPHA-SYNUCLEIN; ANIMALS; COPPER; HUMANS; METALS; MOLECULAR CONFORMATION; NEURONS; OXIDATION-REDUCTION; PARKINSON DISEASE, SECONDARY; PROTEIN FOLDING; PROTEINS;

EID: 38849091518     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21461     Document Type: Short Survey

References (103)

1. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ. 2006. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739-29752.
2. Armstrong RA, Lantos PL, Cairns NJ. 2004. Spatial patterns of alpha-synuclein positive glial cytoplasmic inclusions in multiple system atrophy. Mov Disord 19(1):109-112.
3. Barnham KJ, Masters CL, Bush AI. 2004. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3:205-214.
4. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M. 2005. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A 102:1430-1435.
5. Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M. 2000. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem 275:34574-34579.
6. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM, Fernandez CO. 2006. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc 128:9893-9901.
7. Bodles AM, Guthrie DJ, Harriott P, Campbell P, Irvine GB. 2000. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur J Biochem 267:2186-2194.
8. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. 2002. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249(Suppl 3):III/1-5.
9. Buchman VL, Hunter HJ, Pinon LG, Thompson J, Privalova EM, Ninkina NN, Davies AM. 1998. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J Neurosci 18:9335-9341.
10. Bussell R, Jr., Eliezer D. 2004. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry 43:4810-4818.
11. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. 2002. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclem. J Neurosci 22:8797-8807.
12. Chandra S, Chen X, Rizo J, Jahn R, Sudhof TC. 2003. A broken alpha-helix in folded alpha-synuclein. J Biol Chem 278:15313-15318.
13. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. 2005. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123:383-396.
14. Choi W, Zibaee S, Jakes R, Serpell LC, Davletov B, Crowther RA, Goedert M. 2004. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett 576:363-368.
15. Cole NB, Murphy DD, Lebowitz J, Di Noto L, Levine RL, Nussbaum RL. 2005. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J Biol Chem 280:9678-9690.
16. Conway KA, Harper JD, Lansbury PT. 1998. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-1320.
17. Conway KA, Harper JD, Lansbury PT, Jr. 2000a. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39:2552-2563.
18. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT, Jr. 2000b. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97:571-576.
19. Crowther RA, Jakes R, Spillantini MG, Goedert M. 1998. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 436:309-312.
20. Davidson WS, Jonas A, Clayton DF, George JM. 1998. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443-9449.
21. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM. 2005. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc 127:476-477.
22. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. 1991. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953-1975.
23. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD. 1989. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836.
24. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D, Wallace A. 1998. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440(1-2):71-75.
25. Eliezer D, Kutluay E, Bussell R, Jr, Browne G. 2001. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307:1061-1073.
26. Ellis CE, Schwartzberg PL, Grider TL, Fink DW, Nussbaum RL. 2001. alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J Biol Chem 276:3879-3884.
27. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW. 2004. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55(2):174-179.
28. Farrer MJ. 2006. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7:306-318.
29. Fernandez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, Jovin TM. 2004. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 23:2039-2046.
30. Friedlich AL, Tanzi RE, Rogers JT. 2007. The 5′-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry 12:222-223.
31. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. 2002. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160-164.
32. Gaeta A, Hider RC. 2005. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146:1041-1059.
33. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
34. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. 2001. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276:2380-2386.
35. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. 1999. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274:7619-7622.
36. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B. 2002. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem 277:16116-16123.
37. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. 1999. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20(2-3):239-247.
38. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. 2005. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 280:7800-7807.
39. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E. 1998. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 799:301-306.
40. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E. 1999. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10:717-721.
41. Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H. 2006. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun 341:1088-1095.
42. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. 1991. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56:446-451.
43. Hoyer W, Cherny D, Subramaniam V, Jovin TM. 2004. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43:16233-16242.
44. Iseki E. 2004. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. Neuropathology 24(1):72-78.
45. Jakes R, Spillantini MG, Goedert M. 1994. Identification of two distinct synucleins from human brain. FEBS Lett 345(1):27-32.
46. Kalivendi SV, Cunningham S, Kotamraju S, Joseph J, Hillard CJ, Kalyanaraman B. 2004. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem 279:15240-15247.
47. Khan A, Ashcroft AE, Higenell V, Korchazhkina OV, Exley C. 2005. Metals accelerate the formation and direct the structure of amyloid fibrils of NAC. J Inorg Biochem 99:1920-1927.
48. Kotzbauer PT, Trojanowsk JQ, Lee VM. 2001. Lewy body pathology in Alzheimer's disease. J Mol Neurosci 17:225-232.
49. Kowalik-Jankowska T, Rajewska A, Jankowska E, Grzonka Z. 2006a. Copper(II) binding by fragments of alpha-synuclein containing M1-D2-and -H50-residues; a combined potentiometric and spectroscopic study. Dalton Trans 42:5068-5076.
50. Kowalik-Jankowska T, Rajewska A, Jankowska E, Wisniewska K, Grzonka Z. 2006b. Products of Cu(II)-catalyzed oxidation of the N-terminal fragments of alpha-synuclein in the presence of hydrogen peroxide. J Inorg Biochem 100:1623-1631.
51. Kowalik-Jankowska T, Rajewska A, Wisniewska K, Grzonka Z, Jezierska J. 2005. Coordination abilities of N-terminal fragments of alpha-synuclein towards copper(II) ions: a combined potentiometric and spectroscopic study. J Inorg Biochem 99:2282-2291.
52. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18(2):106-108.
53. Lee EN, Lee SY, Lee D, Kim J, Paik SR. 2003. Lipid interaction of alpha-synuclein during the metal-catalyzed oxidation in the presence of Cu2+ and H2O2. J Neurochem 84:1128-1142.
54. Lee HJ, Choi C, Lee SJ. 2002. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem 277(1):671-678.
55. Liu LL, Franz KJ. 2005. Phosphorylation of an alpha-synuclein peptide fragment enhances metal binding. J Am Chem Soc 127:9662-9663.
56. Liu LL, Franz KJ. 2007. Phosphorylation-dependent metal binding by alpha-synuclein peptide fragments. J Biol Inorg Chem 12(2):234-247.
57. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. 1998. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158(1):47-52.
58. Lowe R, Pountney DL, Jensen PH, Gai WP, Voelcker NH. 2004. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci 13:3245-3252.
59. Mandel S, Maor G, Youdim MB. 2004. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci 24:401-416.
60. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. 2002. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277:1641-1644.
61. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269.
62. McNaught KS, Jenner P. 2001. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 297(3):191-194.
63. Mishizen-Eberz AJ, Guttmann RP, Giasson BI, Day GA, 3rd, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR. 2003. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem 86:836-847.
64. Morita A, Kimura M, Itokawa Y. 1994. The effect of aging on the mineral status of female mice. Biol Trace Elem Res 42(2):165-177.
65. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. 2000. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20:3214-3220.
66. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, Trojanowski JQ, Lee VM. 2003. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42:8530-8540.
67. Nakamura T, Yamashita H, Nagano Y, Takahashi T, Avraham S, Avraham H, Matsumoto M, Nakamura S. 2002. Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases. FEBS Lett 521(1-3):190-194.
68. Nakamura T, Yamashita H, Takahashi T, Nakamura S. 2001. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem Biophys Res Commun 280:1085-1092.
69. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. 1999. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274:9843-9846.
70. Nielsen MS, Vorum H, Lindersson E, Jensen PH. 2001. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem 276:22680-22684.
71. Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R, Tomiyama H, Mizoguchi K, Murata M, Toda T, Imoto I, Inazawa J, Mizuno Y, Hattori N. 2006. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59:298-309.
72. Norris EH, Giasson BI, Ischiropoulos H, Lee VM. 2003. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278:27230-27240.
73. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, Trojanowski JQ, Ishikawa A, Idezuka J, Murata M, Toda T, Bird TD, Leverenz JB, Tsuji S, La Spada AR. 2004. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63:805-811.
74. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. 2000. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048-6054.
75. Paik SR, Shin HJ, Lee JH. 2000. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch Biochem Biophys 378:269-277.
76. Paik SR, Shin HJ, Lee JH, Chang CS, Kim J. 1999. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J 340(Pt 3):821-828.
77. Pall HS, Williams AC, Blake DR, Lunec J, Gutteridge JM, Hall M, Taylor A. 1987. Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 2:238-241.
78. Papadopoulos D, Ewans L, Pham-Dinh D, Knott J, Reynolds R. 2006. Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. Mol Cell Neurosci 31:597-612.
79. Perrin RJ, Woods WS, Clayton DF, George JM. 2001. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem 276:41958-41962.
80. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
81. Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA. 2005. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20:898-906.
82. Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM, Fernandez CO. 2005. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the biomorganic chemistry of Parkinson's disease. Proc Natl Acad Sci U S A 102:4294-4299.
83. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E. 2001. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 914(1-2):48-56.
84. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. 2000. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 97:4897-4902.
85. Shavali S, Carlson EC, Swinscoe JC, Ebadi M. 2004. 1-Benzyl-1,2,3,4- tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells. J Neurosci Res 76:563-571.
86. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841.
87. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. 2003. Aggregated and monomelic alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 278:11753-11759.
88. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. 2000a. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275:18344-18349.
89. Souza JM, Giasson BI, Lee VM, Ischiropoulos H. 2000b. Chaperone-like activity of synucleins. FEBS Lett 474(1):116-119.
90. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95:6469-6473.
91. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
92. Sung YH, Rospigliosi C, Eliezer D. 2006. NMR mapping of copper binding sites in alpha-synuclein. Biochim Biophys Acta 1764(1):5-12.
93. Tofaris GK, Revesz T, Jacques TS, Papacostas S, Chataway J. 2007. Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. Arch Neurol 64:280-282.
94. Uversky VN, Li J, Fink AL. 2001a. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276:44284-44296.
95. Uversky VN, Li J, Fink AL. 2001b. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 500(3):105-108.
96. Uversky VN, Yamin G, Souillac PO, Goers J, Glaser CB, Fink AL. 2002. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett 517(1-3):239-244.
97. Volles MJ, Lansbury PT, Jr. 2003. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42:7871-7878.
98. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. 1996. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35:13709-13715.
99. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. 1999. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274:19509-19512.
100. Yamin G, Glaser CB, Uversky VN, Fink AL. 2003. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem 278:27630-27635.
101. Youdim MB, Ben-Shachar D, Riederer P. 1991. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol 31 Suppl 1:34-40.
102. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164-173.
103. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. 2004. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863-873.